DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
› › 188

Press-release

Decision Resources Study Evaluates the Strategies of Eli Lilly and Other Depression Market Leaders to Combat Generic Competition

Decision Resources Study Evaluates the Strategies of Eli Lilly and Other Depression Market Leaders to Combat Generic Competition

Depression, a new study from Decision Resources, Inc., examines recent trends in the treatment of depression, growing generic competition within...

READ ARTICLE

Press-release

New Treatment Approaches for Depression: Will They Be Able to Fend Off Generics?

New Treatment Approaches for Depression: Will They Be Able to Fend Off Generics?

The U.S. antidepressant market, valued at $8.5 billion in 2000, grew at a 20% annual rate between 1995 and 2000. However, with the loss of patent...

READ ARTICLE

Press-release

Decision Resources Study Projects Robust Growth in the Ovarian Cancer Drug Market

Decision Resources Study Projects Robust Growth in the Ovarian Cancer Drug Market

Ovarian cancer causes more deaths each year than all other gynecological cancers combined. The number of prevalent ovarian cancer cases in the...

READ ARTICLE

Press-release

Decision Resources Study Finds That Domination of the Hormone Replacement Therapy Market Will Shift from Oral Estrogens to Oral Combinations and SERMs

Decision Resources Study Finds That Domination of the Hormone Replacement Therapy Market Will Shift from Oral Estrogens to Oral Combinations and SERMs

The growing number of postmenopausal women translates into new challenges for clinicians as they strive to help women stay healthy during the...

READ ARTICLE

Press-release

Decision Resources, Inc., Launches Innovative Decision Support Tool for Evaluating and Comparing Drug Development Opportunities in Central Nervous System (CNS) Disorders

Decision Resources, Inc., Launches Innovative Decision Support Tool for Evaluating and Comparing Drug Development Opportunities in Central Nervous System (CNS) Disorders

Decision Resources, Inc., today announced the availability of its new, proprietary decision support tool, COMPETITIVE LANDSCAPE ™ for CNS...

READ ARTICLE

Press-release

Pharmacia and Pfizer's Celebrex and Merck's Vioxx Will Soon Compete with Second-Generation Selective COX-2 Inhibitors in the Osteoarthritis Drug Market, According to a Decision Resources Study

Pharmacia and Pfizer's Celebrex and Merck's Vioxx Will Soon Compete with Second-Generation Selective COX-2 Inhibitors in the Osteoarthritis Drug Market, According to a Decision Resources Study

All eyes have been on the first selective COX-2 inhibitors, celecoxib (Pharmacia and Pfizer's Celebrex) and rofecoxib (Merck's Vioxx), for the...

READ ARTICLE

Press-release

Decision Resources Study on Post-Myocardial Infarction Finds AstraZeneca's Rosuvastatin May Become the Statin of Choice by 2005

Decision Resources Study on Post-Myocardial Infarction Finds AstraZeneca's Rosuvastatin May Become the Statin of Choice by 2005

Post-Myocardial Infarction is a new study from Decision Resources, Inc., that examines how the need for better and novel cardioprotective agents to...

READ ARTICLE

Press-release

Novel Asthma Therapies and Combination Agents Will Vie for Market Share, According to a Decision Resources Study

Novel Asthma Therapies and Combination Agents Will Vie for Market Share, According to a Decision Resources Study

Asthma is a new Decision Resources study that examines novel drug development efforts arising from a wealth of research into the pathophysiology of...

READ ARTICLE
Load more